Literature DB >> 14656438

Insights into cyclin groove recognition: complex crystal structures and inhibitor design through ligand exchange.

George Kontopidis1, Martin J I Andrews, Campbell McInnes, Angela Cowan, Helen Powers, Lorraine Innes, Andy Plater, Gary Griffiths, Dougie Paterson, Daniella I Zheleva, David P Lane, Stephen Green, Malcolm D Walkinshaw, Peter M Fischer.   

Abstract

Inhibition of CDK2/CA (cyclin-dependent kinase 2/cyclin A complex) activity through blocking of the substrate recognition site in the cyclin A subunit has been demonstrated to be an effective method for inducing apoptosis in tumor cells. We have used the cyclin binding motif (CBM) present in the tumor suppressor proteins p21(WAF1) and p27(KIP1) as a template to optimize the minimal sequence necessary for CDK2/CA inhibition. A series of peptides were prepared, containing nonnatural amino acids, which possess nano- to micromolar CDK2-inhibitory activity. Here we present X-ray structures of the protein complex CDK2/CA, together with the cyclin groove-bound peptides H-Ala-Ala-Abu-Arg-Ser-Leu-Ile-(p-F-Phe)-NH(2) (peptide 1), H-Arg-Arg-Leu-Ile-Phe-NH(2) (peptide 2), Ac-Arg-Arg-Leu-Asn-(m-Cl-Phe)-NH(2) (peptide 3), H-Arg-Arg-Leu-Asn-(p-F-Phe)-NH(2) (peptide 4), and H-Cit-Cit-Leu-Ile-(p-F-Phe)-NH(2) (peptide 5). Some of the peptide complexes presented here were obtained through the novel technique of ligand exchange within protein crystals. This method may find general application for obtaining complex structures of proteins with surface-bound ligands.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14656438     DOI: 10.1016/j.str.2003.11.006

Source DB:  PubMed          Journal:  Structure        ISSN: 0969-2126            Impact factor:   5.006


  14 in total

1.  Targeting the cyclin-binding groove site to inhibit the catalytic activity of CDK2/cyclin A complex using p27(KIP1)-derived peptidomimetic inhibitors.

Authors:  Arumugasamy Karthiga; Sunil Kumar Tripathi; Ramasamy Shanmugam; Venkatesan Suryanarayanan; Sanjeev Kumar Singh
Journal:  J Chem Biol       Date:  2014-09-18

2.  Quantification of the effects of ionic strength, viscosity, and hydrophobicity on protein-ligand binding affinity.

Authors:  Christos P Papaneophytou; Asterios I Grigoroudis; Campbell McInnes; George Kontopidis
Journal:  ACS Med Chem Lett       Date:  2014-07-09       Impact factor: 4.345

3.  Structural and biochemical studies of human proliferating cell nuclear antigen complexes provide a rationale for cyclin association and inhibitor design.

Authors:  George Kontopidis; Su-Ying Wu; Daniella I Zheleva; Paul Taylor; Campbell McInnes; David P Lane; Peter M Fischer; Malcolm D Walkinshaw
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-28       Impact factor: 11.205

4.  Structural and functional analysis of cyclin D1 reveals p27 and substrate inhibitor binding requirements.

Authors:  Shu Liu; Joshua K Bolger; Lindsay O Kirkland; Padmavathy N Premnath; Campbell McInnes
Journal:  ACS Chem Biol       Date:  2010-10-14       Impact factor: 5.100

5.  Efficient soluble expression of active recombinant human cyclin A2 mediated by E. coli molecular chaperones.

Authors:  Asterios I Grigoroudis; Campbell McInnes; Padmavathy Nandha Premnath; George Kontopidis
Journal:  Protein Expr Purif       Date:  2015-05-06       Impact factor: 1.650

6.  Fragment based discovery of arginine isosteres through REPLACE: towards non-ATP competitive CDK inhibitors.

Authors:  Padmavathy Nandha Premnath; Shu Liu; Tracy Perkins; Jennifer Abbott; Erin Anderson; Campbell McInnes
Journal:  Bioorg Med Chem       Date:  2013-11-07       Impact factor: 3.641

Review 7.  Selectivity and potency of cyclin-dependent kinase inhibitors.

Authors:  Jayalakshmi Sridhar; Nagaraju Akula; Nagarajan Pattabiraman
Journal:  AAPS J       Date:  2006-03-24       Impact factor: 4.009

8.  Optimization of non-ATP competitive CDK/cyclin groove inhibitors through REPLACE-mediated fragment assembly.

Authors:  Shu Liu; Padmavathy Nandha Premnath; Joshua K Bolger; Tracy L Perkins; Lindsay O Kirkland; George Kontopidis; Campbell McInnes
Journal:  J Med Chem       Date:  2013-02-12       Impact factor: 7.446

9.  Benzamide capped peptidomimetics as non-ATP competitive inhibitors of CDK2 using the REPLACE strategy.

Authors:  Padmavathy Nandha Premnath; Sandra N Craig; Shu Liu; Campbell McInnes
Journal:  Bioorg Med Chem Lett       Date:  2016-06-10       Impact factor: 2.823

10.  Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors.

Authors:  Padmavathy Nandha Premnath; Sandra Craig; Campbell McInnes
Journal:  J Vis Exp       Date:  2015-10-26       Impact factor: 1.355

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.